How to Manage Estrogen on TRT

Aromatase is an enzyme, something called CYP19A1, that converts testosterone into estradiol. That one sentence explains almost every estrogen problem men run into on TRT, and almost every mistake providers make when trying to fix those problems.

Before getting into the mechanism, here is the full chain so you can see where everything fits. You inject testosterone. Your body produces aromatase in multiple tissues, but especially in body fat. The aromatase grabs testosterone and converts it into estradiol. Your estradiol level rises. Your provider sees a number on a lab report and reaches for anastrozole to block the enzyme. The estrogen drops. And now you have a different problem. That is the whole cycle, and the article is about why step four is where most people go wrong.

Aromatase is not doing something wrong. It is doing exactly what it is supposed to do, which is produce estradiol from testosterone, and men need that estradiol. Approximately 80% of the estradiol circulating in a man's blood comes from peripheral aromatization, meaning conversion happening out in the tissues, primarily fat, rather than directly from the testes. The other 20% comes from the testes directly. So when you block aromatase systemically with a drug like anastrozole, you are not trimming estrogen around the edges. You are cutting off the primary production pathway.

The Finkelstein study, published in the New England Journal of Medicine in 2013, ran exactly that experiment. Four hundred healthy men aged 20 to 50 had their natural testosterone production suppressed, then received testosterone at various doses with or without anastrozole to block aromatization. The result was that estrogen deficiency, not testosterone deficiency, was the primary driver of fat accumulation. Subcutaneous fat area increased two to three times in the groups with suppressed estrogen. Sexual desire declined significantly with a P value below 0.001, and erectile function declined with a P value of 0.022, even with testosterone still present. What that study proved is that estrogen has independent, non-negotiable functions in male physiology that testosterone cannot cover for.

A separate trial published in the Journal of Clinical Endocrinology and Metabolism in 2009 gave 69 men over the age of 60 either 1 mg of anastrozole daily or a placebo for 12 months. Estradiol fell by roughly 20%, from about 15 to about 12 pg/mL. That relatively modest drop produced a statistically significant decline in spinal bone mineral density, with a P value of 0.0014. The takeaway is not that low estrogen causes some bone loss. The takeaway is that you can measure it happening in one year from a 20% reduction. Scale that forward over years of AI use and the numbers compound.

So estrogen is not the enemy. It is the signal going off that something in the system is being driven too hard, and the question worth asking before prescribing a drug to suppress it is: what is doing the driving?

Aromatase conversion is substrate-driven, meaning the enzyme converts more testosterone into estradiol when more testosterone is available to convert. This is not a hormone disorder. It is chemistry. If you give the enzyme more raw material, it produces more product. That mechanism is what makes injection frequency so important.

Testosterone cypionate has an elimination half-life of approximately 4.5 days and a mean residence time of approximately 8.5 days. When someone injects a full weekly dose at once, testosterone peaks within 24 to 48 hours after injection, and estradiol trails that peak by about one to two days, cresting around day three or four. That trailing peak is estradiol responding to the flood of substrate. Then by day seven, testosterone has declined significantly before the next injection, creating a trough that leaves the person cycling between supraphysiologic highs and sub-therapeutic lows. Splitting that same weekly dose into two injections reduces peak-to-trough variance by approximately 30%. Daily subcutaneous injections, replicating the body's natural output of roughly 6 to 7 mg per day, smooth this out further. The total testosterone dose over the week does not change. The total estrogen production over the week may remain similar. But the spikes are what produce the symptoms, and flattening the spikes flattens the symptoms.

Injection frequency is the most direct lever, but it is not the only one. Aromatase is expressed in adipose tissue and its activity in that tissue is driven by glucocorticoids, inflammatory cytokines like TNF-alpha, and class 1 cytokines through a specific region of the aromatase gene called promoter I.4. Men with higher body fat have more aromatase-expressing tissue, more enzyme, and more conversion at any given testosterone dose. Chronic stress elevates cortisol, which activates that same promoter. Poor sleep elevates cortisol and inflammatory markers. Alcohol directly increases aromatase activity. Insulin resistance affects both aromatase expression and something called SHBG, which is sex hormone-binding globulin, the protein that binds testosterone and determines how much of it is free and available for conversion. Genetics also vary, individual CYP19A1 expression differs meaningfully between people, which is why two men on identical doses can have different estradiol levels.

The clinical trap that develops when none of this is addressed looks like this: a man starts weekly testosterone injections, develops symptoms from high estradiol peaks, gets prescribed anastrozole, develops low estrogen symptoms including joint pain, depression, and erectile dysfunction from the suppression, and the clinic then spends months adjusting the AI dose trying to find a stable number. The patient is now on two drugs managing a problem that injection frequency changes and lifestyle modifications would likely solve without suppressing estrogen at all.

Before any of that management can happen, you need accurate data. Standard immunoassay estradiol tests used in most labs cross-react with other steroids in men and can give inaccurate readings. The test that matters is called LC-MS/MS, or liquid chromatography tandem mass spectrometry, which is the sensitive estradiol test designed specifically for male physiology. Typical targets for men on standard TRT doses run somewhere between 20 and 35 pg/mL, with 40 to 60 being acceptable at higher doses if the person is feeling well and has no symptoms.

One note on the evidence for injection frequency specifically: the pharmacokinetic logic is well-established, aromatase is substrate-driven, more frequent injections produce smaller testosterone peaks, smaller peaks mean smaller estradiol spikes. That mechanism is sound. But a dedicated randomized trial comparing weekly versus twice-weekly versus daily injections with estradiol as the primary endpoint has not been done. The clinical observation is strong, the mechanism is clear, and the pharmacokinetics are well-documented. A head-to-head RCT showing that switching frequency eliminates the need for an AI has not yet been published.

The practical sequence is: get an LC-MS/MS estradiol test to know where you actually are, then look at the drivers before touching the enzyme. Injection frequency first because it is the most direct. Then body composition, sleep, alcohol, and stress. An aromatase inhibitor belongs at the end of that list, after those variables have been addressed, not at the front because a number on a lab report looked high.

Estrogen on TRT is usually a protocol problem dressed up as a hormone problem, and the difference between treating the protocol and suppressing the enzyme is the difference between working with your physiology and working around it.

---

References

1. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. 2013. Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. New England Journal of Medicine, 36911, 1011-1022. Source
2. Burnett-Bowie SM, McKay EA, Lee H, Leder BZ. 2009. Effects of Aromatase Inhibition on Bone Mineral Density and Bone Turnover in Older Men with Low Testosterone Levels. Journal of Clinical Endocrinology and Metabolism, 9412, 4785-4792. Source
3. Pastuszak AW, et al. 2022. Pharmacokinetics of Testosterone Cypionate Delivered via Subcutaneous Autoinjector. Andrology. Source
4. Chand AL, et al. (2015). Weight gain and inflammation regulate aromatase expression in male adipose tissue. Journal of Steroid Biochemistry and Molecular Biology.
5. Bhasin S, Brito JP, Cunningham GR, et al. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. JCEM, 103(5), 1715-1744.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness